Abstract
Objective: The purpose of this open-label study was to describe the effectiveness of aripiprazole (APZ) in the treatment of children with bipolar disorders suffering from manic symptomatology. Method: Symptomatic outpatients (Young Mania Rating Scale [YMRS] score ≥15) meeting strict, unmodified, Diagnostic and Statistical Manual of Mental Disorders, 4th edition, diagnostic symptom criteria for a bipolar disorder, ages 4-9 years, were eligible. Subjects were treated prospectively with flexible doses of APZ (maximum daily dose of 15 mg/day), for up to 16 weeks or until a priori response criteria were met. Outcome measures included the YMRS, Clinical Global Impressions Scale-Severity, Children's Global Assessment Scale (CGAS), and the Children's Depression Rating Scale-Revised (CDRS-R). A priori response criteria consisted of 3 of 4 consecutive weeks with (1) CDRS-R 50. Results: Ninety-six children (62 males; mean age of 6.9 (SD = 1.7), received APZ for an average length of treatment of 12.5 (SD = 3.9) weeks. Significant improvements in YMRS, CDRS-R, CGAS, and Clinical Global Impressions Scale-Severity scores (p <0.001) were noted at the end of study participation. Sixty of the subjects (62.5%) met a priori response criteria at study's end. The most common side effects noted were stomachache, increased appetite, and headache. Two subjects were removed from the study due to side effects [epistaxis (n = 1); akathisia (n = 1)]. Subjects experienced an average weight gain of 2.4 (SD = 1.9) kg. Conclusion: APZ may be effective in the acute treatment of symptoms of children with bipolar illnesses.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 345-351 |
| Number of pages | 7 |
| Journal | Journal of Child and Adolescent Psychopharmacology |
| Volume | 21 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 1 2011 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
- Pediatrics, Perinatology, and Child Health
- Psychiatry and Mental health
Cite this
An open-label study of aripiprazole in children with a bipolar disorder. / Findling, Robert L; McNamara, Nora K.; Youngstrom, Eric A.; Stansbrey, Robert J.; Frazier, Thomas W.; Lingler, Jacqui; Otto, Benjamin D.; Demeter, Christine A.; Rowles, Brieana M.; Calabrese, Joseph R.
In: Journal of Child and Adolescent Psychopharmacology, Vol. 21, No. 4, 01.08.2011, p. 345-351.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - An open-label study of aripiprazole in children with a bipolar disorder
AU - Findling, Robert L
AU - McNamara, Nora K.
AU - Youngstrom, Eric A.
AU - Stansbrey, Robert J.
AU - Frazier, Thomas W.
AU - Lingler, Jacqui
AU - Otto, Benjamin D.
AU - Demeter, Christine A.
AU - Rowles, Brieana M.
AU - Calabrese, Joseph R.
PY - 2011/8/1
Y1 - 2011/8/1
N2 - Objective: The purpose of this open-label study was to describe the effectiveness of aripiprazole (APZ) in the treatment of children with bipolar disorders suffering from manic symptomatology. Method: Symptomatic outpatients (Young Mania Rating Scale [YMRS] score ≥15) meeting strict, unmodified, Diagnostic and Statistical Manual of Mental Disorders, 4th edition, diagnostic symptom criteria for a bipolar disorder, ages 4-9 years, were eligible. Subjects were treated prospectively with flexible doses of APZ (maximum daily dose of 15 mg/day), for up to 16 weeks or until a priori response criteria were met. Outcome measures included the YMRS, Clinical Global Impressions Scale-Severity, Children's Global Assessment Scale (CGAS), and the Children's Depression Rating Scale-Revised (CDRS-R). A priori response criteria consisted of 3 of 4 consecutive weeks with (1) CDRS-R 50. Results: Ninety-six children (62 males; mean age of 6.9 (SD = 1.7), received APZ for an average length of treatment of 12.5 (SD = 3.9) weeks. Significant improvements in YMRS, CDRS-R, CGAS, and Clinical Global Impressions Scale-Severity scores (p <0.001) were noted at the end of study participation. Sixty of the subjects (62.5%) met a priori response criteria at study's end. The most common side effects noted were stomachache, increased appetite, and headache. Two subjects were removed from the study due to side effects [epistaxis (n = 1); akathisia (n = 1)]. Subjects experienced an average weight gain of 2.4 (SD = 1.9) kg. Conclusion: APZ may be effective in the acute treatment of symptoms of children with bipolar illnesses.
AB - Objective: The purpose of this open-label study was to describe the effectiveness of aripiprazole (APZ) in the treatment of children with bipolar disorders suffering from manic symptomatology. Method: Symptomatic outpatients (Young Mania Rating Scale [YMRS] score ≥15) meeting strict, unmodified, Diagnostic and Statistical Manual of Mental Disorders, 4th edition, diagnostic symptom criteria for a bipolar disorder, ages 4-9 years, were eligible. Subjects were treated prospectively with flexible doses of APZ (maximum daily dose of 15 mg/day), for up to 16 weeks or until a priori response criteria were met. Outcome measures included the YMRS, Clinical Global Impressions Scale-Severity, Children's Global Assessment Scale (CGAS), and the Children's Depression Rating Scale-Revised (CDRS-R). A priori response criteria consisted of 3 of 4 consecutive weeks with (1) CDRS-R 50. Results: Ninety-six children (62 males; mean age of 6.9 (SD = 1.7), received APZ for an average length of treatment of 12.5 (SD = 3.9) weeks. Significant improvements in YMRS, CDRS-R, CGAS, and Clinical Global Impressions Scale-Severity scores (p <0.001) were noted at the end of study participation. Sixty of the subjects (62.5%) met a priori response criteria at study's end. The most common side effects noted were stomachache, increased appetite, and headache. Two subjects were removed from the study due to side effects [epistaxis (n = 1); akathisia (n = 1)]. Subjects experienced an average weight gain of 2.4 (SD = 1.9) kg. Conclusion: APZ may be effective in the acute treatment of symptoms of children with bipolar illnesses.
UR - http://www.scopus.com/inward/record.url?scp=80052102832&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052102832&partnerID=8YFLogxK
U2 - 10.1089/cap.2010.0102
DO - 10.1089/cap.2010.0102
M3 - Article
C2 - 21823912
AN - SCOPUS:80052102832
VL - 21
SP - 345
EP - 351
JO - Journal of Child and Adolescent Psychopharmacology
JF - Journal of Child and Adolescent Psychopharmacology
SN - 1044-5463
IS - 4
ER -